Moreover, our study failed to reveal significant difference for OS when NSCLC patients were grouped according to KRAS genotype detected in cfDNA (HR, 1.05; 95% CI, 0.49-2.25; P = 0.892; Figure 6B). This evidence concerns the gene KRAS and non-small cell lung carcinoma.